CELG Celgene Corp.

108.300.17 (+0.16%)
IEX price: 3:59:59 PM

Quote

Previous Close
-
Day Range
-
52 Week Range
$58.59-$110.70
Volume
190,935,421
Avg Volume
5,639,710
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$77.08B
Enterprise Value (EV)
$91.19B
PE Ratio
12.99
EV/EBITDA
12.29
Price/Sales
5.03
Price/Book
12.50
PEG Ratio
0.42

Financials

Revenue
$15.29B
Gross Profit
$14.24B
EBITDA
$7.42B
EPS, ttm
$8.34
Profit Margin
26.46%
Revenue/Employee
$1.73M
Next Earnings Date
1/27/2020 (68 days)
Debt to Equity
329%
Debt
$20.15B
Cash
$6.04B
Net Debt
$14.11B

Performance

Beta
0.58
200 Day Moving Avg
$95.50
50 Day Moving Avg
$103.04
52 Week Change
61.99%
YTD Change
62.42%
1 Month Change
4.57%
3 Month Change
13.51%
6 Month Change
14.03%
1 Year Change
61.99%
2 Year Change
4.83%
5 Year Change
1.07%

Share Count

Shares Outstanding
711.7M
Float
710.9M
Restricted Shares
829.9K
Restricted Shares, %
0.12%

Celgene Corp. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Mark J. Alles

Website: http://www.celgene.com

Description: Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include REVLIMID, POMALYST, IMNOVID, OTEZLA, ABRAXANE, and VIDAZA. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ.

Employees: 8,852

Latest News